|Bid||60.94 x 200|
|Ask||61.62 x 300|
|Day's Range||60.98 - 61.74|
|52 Week Range||46.01 - 66.10|
|PE Ratio (TTM)||22.37|
|Forward Dividend & Yield||1.56 (2.54%)|
|1y Target Est||N/A|
Tecentriq, a cancer immunotherapy developed by the Swiss drug giant Roche, slowed the progression of previously untreated lung cancer in a large clinical trial when combined with a chemotherapy regimen, the drug giant said.
Merck & Co., Inc. (NYSE:MRK) did not finish last week well. MRK stock hit its 52-week low on the news. As I’ve said many times before, this is when contrarian investors need to take a deeper dive and see if a great long-term company like Merck stock has been oversold, or whether it’s being justly punished for its shortcomings.
If you notice a relative who can't stop grinning at the Thanksgiving dinner table, they're probably holding shares of these biotech stocks.
Cancer immunotherapies and targeted therapies offer renewed hope to lung-cancer patients.
Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold."
Ever since its cholesterol-fighting drug Lipitor lost the crux of its patent protection back in 2011, Pfizer Inc. (NYSE:PFE) investors have approached PFE stock with caution. Early this week, Purkiss made a point of saying sales of Ibrance is being underestimated, suggesting that rather than achieving just a little less than $7 billion in revenue in 2023, it could actually produce nearly $13-billion worth of business that year as its approved uses were expanded and caregivers saw its efficacy.
Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.
After Heron Therapeutics Inc (NASDAQ: HRTX ), Bristol-Myers Squibb Co (NYSE: BMY ) and Dynavax Technologies Corporation (NASDAQ: DVAX ) found favor with the FDA, it's Ultragenyx Pharmaceutical Inc (NASDAQ: ...
Arcus Biosciences Inc. has secured $107 million to develop an arsenal of cancer immunotherapies.
Nektar (NKTR) and partner Bristol-Myers share positive interim data from dose-escalation part of a phase I/II study, evaluating NKTR-214 with Opdivo across three tumor types.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Bristol-Myers Squibb Co. Here are 5 ETFs with the largest exposure to BMY-US. Comparing the performance and risk of Bristol-Myers Squibb Co. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Everyone has heard the talk. Pfizer (PFE) is getting ready to make a deal. the skinny on Wall Street is that the U.S. pharmaceutical giant has its eyes set on rival Bristol-Myers Squibb (BMY) and its immuno-oncology ...
Shares of Nektar Therapeutics soared 26% in premarket trade Monday, putting them on track to open at the highest level seen since January 2001, after the biopharmaceutical company announced over the weekend ...
With a market capitalization of USD $102.42B, Bristol-Myers Squibb Company (NYSE:BMY) falls in the category of stocks popularly identified as large-caps. These are established companies that attract investors due toRead More...
Of the 31 analysts tracking Celgene (CELG) in November 2017, 11 analysts recommended a “strong buy” while eight analysts recommended a “buy.”
Most big pharma companies will actually lose market share over the next few years. These three will gain market share -- but in very different ways.
Outcome Health, co-founded by Chicago entrepreneur Rishi Shah, is losing major advertisers after allegations surfaced that employees were misleading clients. Bristol-Myers Squibb Co. (BMY) will not renew its ad agreement for 2018 with the Chicago-based startup, according to The Wall Street Journal . Bristol-Myers was expected to pay Outcome about $20 million in 2017, according to Journal sources familiar with the deal.
Of the 22 analysts covering Bristol-Myers Squibb, nine analysts recommend a “buy,” 11 analysts recommend a “hold,” and two analysts recommend a “sell.”
The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical